{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:04:31Z","timestamp":1790697871953,"version":"4.1.0"},"reference-count":49,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To determine the economic impact of insurance company prior authorizations for antivascular endothelial growth factor (anti-VEGF) therapies on society.\n                    <jats:bold>Methods:<\/jats:bold>\n                    Prior authorization denial and delay rates were derived from a large electronic database (SamaCare PA). Data were analyzed in a theoretical cost-effectiveness model to calculate the increased costs of prior authorizations (in 2025 US dollars).\n                    <jats:bold>Results:<\/jats:bold>\n                    Of 33 178 total prior authorization requests, the majority were from Medicare Advantage plans (18 769, 58.2%), followed by commercial insurance carriers (10 047, 31.1%) and Medicaid (3438, 10.7%). Commercial carriers had the highest mean prior authorization denial rates and approval delays (3.95% denials, 4.95 days delayed), followed by Medicaid (3.87% denials, 4.11 days delayed) and Medicare Advantage (1.18% denials, 1.54 days delayed). Over the average patient\u2019s lifetime, the prior authorization process increased total societal costs by a mean $10 842.24 (range, $228.11\u2013$90 322.69), and the direct savings from denying a prior authorization was only $27.11 per injection (range, $3.06\u2013$49.99). Each prior authorization request increased the mean total societal costs by an additional $637.78 in the reference case (range, $25.35\u2013$4105.58). Prior authorizations annually cost the workplace an extra $588.17 (range, $9.98\u2013$3513.90), the patient and family an extra $362.92 (range, $20.93\u2013$1743.63), the provider an extra $11.61 (range, $1.14\u2013$324.18), and the insurer an extra $4.92 per year (range, \u2212$40.85 to $76.03). Prior authorizations were not cost saving in &gt;99.9% of modeled scenarios. Insurance companies were the only sector of society to potentially save money.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Prior authorization requests were ultimately approved in 97.7% of all cases, with 97.9% being delayed. The prior authorization process was not cost-saving and increased the total societal costs of anti-VEGF treatments.\n                  <\/jats:p>","DOI":"10.1177\/24741264251381151","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T12:35:31Z","timestamp":1762950931000},"page":"38-45","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Economic Impact of Antivascular Endothelial Growth Factor Prior Authorization Process From a Large Electronic Database"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4874-2471","authenticated-orcid":false,"given":"Ella H.","family":"Leung","sequence":"first","affiliation":[{"name":"Georgia Retina, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-9429","authenticated-orcid":false,"given":"Saira","family":"Khanna","sequence":"additional","affiliation":[{"name":"The Retina Institute, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Lai","sequence":"additional","affiliation":[{"name":"Retina Group of Washington, Chevy Chase, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-5091","authenticated-orcid":false,"given":"Charles","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Jumper","sequence":"additional","affiliation":[{"name":"West Coast Retina, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Blim","sequence":"additional","affiliation":[{"name":"American Society of Retina Specialists, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabin","family":"Dang","sequence":"additional","affiliation":[{"name":"The Retina Institute, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30489-7"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.4557"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/09286586.2024.2310854"},{"key":"e_1_3_2_5_2","unstructured":"Centers for Medicare & Medicaid Services Data. Medicare Part B spending by drug. CMS Data. 2024. Accessed December 19 2024. https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/medicare-part-b-spending-by-drug"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.25259\/IHOPEJO_37_2022"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31816c6868"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.21428"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2021.1903514"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00775"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2023.89394"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.36648\/1791-809X.21.15.833"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.362"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.2217"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100421"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.05.017"},{"key":"e_1_3_2_17_2","unstructured":"Social Security Administration. Actuarial life table. 2022. Accessed October 15 2024. https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html"},{"key":"e_1_3_2_18_2","unstructured":"U.S. Bureau of Labor and Statistics. Median usual weekly earnings of full-time wage and salary worker by age and sex. 2025. Accessed January 2 2025. https:\/\/www.bls.gov\/charts\/usual-weekly-earnings\/usual-weekly-earnings-current-quarter-by-age.htm"},{"key":"e_1_3_2_19_2","unstructured":"U.S. Bureau of Labor and Statistics. Employment status of the civilian noninstitutional population by age sex and race. 2022. Accessed December 19 2024. https:\/\/www.bls.gov\/cps\/cpsaat03.pdf"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/11206721231185808"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000164"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.03.492"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.10.010"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.08.015"},{"key":"e_1_3_2_25_2","unstructured":"US Census Bureau. United States commuting at a glance: American Community Survey 1-year estimates. Census.gov. 2024. Accessed November 11 2024. https:\/\/www.census.gov\/topics\/employment\/commuting\/guidance\/acs-1yr.html"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003169"},{"key":"e_1_3_2_27_2","unstructured":"CMS. Part B national summary data file (previously known as BESS). 2024. Accessed January 6 2025. https:\/\/www.cms.gov\/data-research\/statistics-trends-and-reports\/part-b-national-summary-data-file"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.09.013"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.3109\/09286586.2015.1066394"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30329-2"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100852"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.01.068"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1529-1839(04)70009-3"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1052"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-023-02261-x"},{"key":"e_1_3_2_36_2","unstructured":"National Association of Insurance Comissioners. U.S. Health insurance industry analysis report. 2021. Accessed January 5 2025. https:\/\/content.naic.org\/sites\/default\/files\/inline-files\/2020-Annual-Health-Insurance-Industry-Analysis-Report.pdf"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1159\/000540390"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.07.060"},{"key":"e_1_3_2_39_2","unstructured":"National Association of Insurance Comissioners. U.S. health insurance industry analysis report. 2023. Accessed January 12 2025. https:\/\/content.naic.org\/sites\/default\/files\/topics-industry-snapshot-analysis-reports-2023-annual-report-health.pdf"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-024-08876-7"},{"key":"e_1_3_2_41_2","unstructured":"Pierson B. Lawsuit claims UnitedHealth AI wrongfully denies elderly extended care. Reuters. November 14 2023. Accessed January 12 2025. https:\/\/www.reuters.com\/legal\/lawsuit-claims-unitedhealth-ai-wrongfully-denies-elderly-extended-care-2023-11-14\/"},{"key":"e_1_3_2_42_2","unstructured":"AP News. Cigna health giant accused of improperly rejecting thousands of patient claims using an algorithm. AP News. July 26 2023. Accessed January 12 2025. https:\/\/apnews.com\/article\/cigna-california-health-coverage-lawsuit-4543b47cd6057519a7e8dc6d90a61866"},{"key":"e_1_3_2_43_2","unstructured":"Grimm CA. High rates of prior authorization denials by some plans and limited state oversight raise concerns about access to care in Medicaid managed care. Office of Inspector General Government Oversight U.S. Department of Health and Human Services. July 17 2023. Accessed January 12 2025. https:\/\/oig.hhs.gov\/reports\/all\/2023\/high-rates-of-prior-authorization-denials-by-some-plans-and-limited-state-oversight-raise-concerns-about-access-to-care-in-medicaid-managed-care\/"},{"key":"e_1_3_2_44_2","unstructured":"American Hospital Association. Addressing commercial health plan abuses to ensure fair coverage for patients and providers. 2020. Accessed January 5 2025. https:\/\/www.aha.org\/system\/files\/media\/file\/2020\/12\/addressing-commercial-health-plan-abuses-ensure-fair-coverage-patients-providers.pdf"},{"key":"e_1_3_2_45_2","unstructured":"Grimm CA. Some Medicare Advantage organization denials of prior authorization requests raise concerns about beneficiary access to medically necessary care. Office of Inspector General Government Oversight U.S. Department of Health and Human Services. April 27 2022. Accessed January 3 2025. https:\/\/oig.hhs.gov\/reports\/all\/2022\/some-medicare-advantage-organization-denials-of-prior-authorization-requests-raise-concerns-about-beneficiary-access-to-medically-necessary-care\/"},{"key":"e_1_3_2_46_2","unstructured":"Guidance Portal. Medicare parts A and B coverage and prior authorization. November 30 2024. Accessed January 4 2025. https:\/\/www.hhs.gov\/guidance\/document\/medicare-parts-and-b-coverage-and-prior-authorization-0"},{"key":"e_1_3_2_47_2","unstructured":"American Medical Association. AMA prior authorization physician survey. 2024. Accessed January 4 2025. https:\/\/www.ama-assn.org\/system\/files\/prior-authorization-survey.pdf"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2013.01.120062"},{"key":"e_1_3_2_49_2","unstructured":"CAQH Insights. 2023 CAQH Index report. 2023. Accessed December 19 2024. https:\/\/www.caqh.org\/hubfs\/43908627\/drupal\/2024-01\/2023_CAQH_Index_Report.pdf"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006535"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251381151","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264251381151","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251381151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:24:36Z","timestamp":1790695476000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264251381151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/24741264251381151"],"URL":"https:\/\/doi.org\/10.1177\/24741264251381151","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}